Meronem Iv (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This leads to weakened cell walls, osmotic instability and ultimately bacterial cell lysis. Its broad affinity for multiple PBPs gives it activity against many resistant Gram‑negative, Gram‑positive and anaerobic bacteria.

The dose of Meronem Iv is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function and local susceptibility patterns. Typical regimens range from 0.5 g to 2 g administered intravenously every 8 hours, but exact dosing must be determined by the treating physician.

Safety data for meropenem in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should discuss potential exposure with their healthcare provider, as the drug may be excreted in breast milk.

To request Meronem Iv, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Meropenem offers a broad spectrum of activity, including stability against many extended‑spectrum β‑lactamases, and penetrates the central nervous system better than some carbapenems. Compared with alternatives such as imipenem‑cilastatin, meropenem has a lower risk of seizures and does not require co‑administration of cilastatin, making it a preferred option for many severe infections.

Meronem Iv must be stored refrigerated at 2 °C to 8 °C, protected from light, and should never be frozen. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept at controlled room temperature if not administered immediately.

Meronem Iv is given by intravenous infusion. The powder is reconstituted with the appropriate diluent, then further diluted in compatible IV fluids. Administration is typically over 30 minutes, but infusion time may be adjusted based on patient tolerance and clinical judgment. Infusion sets should be changed after each use.

Serious adverse events include seizures, especially in patients with renal dysfunction or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant neutropenia or agranulocytosis. Prompt recognition and medical intervention are essential if any of these occur.

Meronem Iv is contraindicated in patients with a documented hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with a history of severe seizures, uncontrolled epilepsy, or those receiving concomitant drugs that lower the seizure threshold.